Position in KRYS
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$2,424,031
+$1,775,390 QoQ
Shares Held
6,522
+159.7% QoQ
Ownership
0.022%
of shares outstanding
% of Portfolio
0.22%
of 13F equity value
Holder Rank
#151
of 422 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KRYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TRANSCEND CAPITAL ADVISORS, LLC holds $6,758,569 across 9 Biotechnology names. KRYS ranks #1 (35.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KRYS |
Krystal Biotech, Inc.
This page
|
6,522 | $2,424,031 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,971 | $1,475,784 | |
| 3 | INCY |
Incyte Corp
|
8,231 | $933,066 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
901 | $561,809 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
8,658 | $475,670 | |
| 6 | EXEL |
Exelixis, Inc.
|
6,283 | $341,858 | |
| 7 | CLDX |
Celldex Therapeutics, Inc.
|
6,196 | $230,553 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
3,912 | $223,844 |
All Filings in KRYS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,424,031 | 6,522 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $648,641 | 2,511 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $414,187 | 1,680 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $296,570 | 1,680 | Shares | Sole | 2025-11-04 | |
| 2025-03-31 | $249,354 | 1,383 | Shares | Sole | 2025-04-24 | |
| 2024-12-31 | $216,504 | 1,382 | Shares | Sole | 2025-02-03 | |
| 2024-09-30 | $251,565 | 1,382 | Shares | Sole | 2024-10-15 | |
| No filing history on record for this holder in this stock. | ||||||